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Abstract By utilizing an L-serine-derived bicyclic lactone as an ad-
vanced chiral building block, a short synthetic route to the cytotoxic
marine natural product jaspine B has been developed. Targeting struc-
ture–activity relationship investigations, the synthetic route has also
been utilized for the synthesis and cytotoxicity evaluation of strategical-
ly modified jaspine B analogues. In addition, a previously reported syn-
thesis of the title natural product from our research has been reinvesti-
gated to clarify the sterochemical assignment.
Key words jaspine B, stereochemistry, cytotoxic, drug development,
structure–activity relationships
The marine natural product jaspine B (Scheme 1), also
known as pachastrissamine, was isolated independently
from two different sponges Pachastrissa sp (2002),3a and
Jaspis sp (2003).3b The all-syn-trisubstituted tetrahydrofu-
ran framework of this novel compound represents the first
example of a cyclic anhydrophytosphingosine structural
feature in a natural product. In biological assays, jaspine B
exhibited submicromolar cytotoxicity (IC50 ≤ 0.5 μM)
against several different cancer cell lines.3 It was shown to
inhibit murine B16, and human Sk-Mel28 melanoma cells
in a time- and dose-dependent manner. Exposure of these
cells to jaspine B triggered cell death by typical apoptosis, as
indicated by phosphatidylserine externalization, the release
of cytochrome c and caspase processing.4 It has been in-
ferred that interference with ceramide metabolism via inhi-
bition of sphingomyelin synthase is probably responsible
for the apoptotic effects of this natural product.4 In further
support of the above mechanistic pathway, jaspine B-in-
duced cell death was enhanced in cells deficient in sphingo-
myelin synthase, whereas, in human cells overexpressing
sphingomyelin synthase, cell death was strongly inhibited.4
In more recent studies, it has also been reported that jas-
pine B is an inhibitor of sphingosine kinases 1 and 2 (Sphk1
and SphK2), and atypical protein kinase C.5a In another
mechanism of action study, jaspine B-induced apoptosis in
melanoma cells has been attributed to inhibition of cyclin-
dependent kinase 2 (Cdk2) production, and extracellular
regulatory kinase (ERK)-mediated down regulation of
FOXO3.5b Since its isolation, the interesting structural fea-
tures and exciting anticancer potential of jaspine B have
made it a popular target for synthesis, resulting in a num-
ber of publications reporting an impressive array of total
synthetic routes to this bioactive natural product.6,7 In con-
trast, studies aimed at identification of the essential phar-
macophore of jaspine B, and correlating its structural fea-
tures with biological activity are still evolving, and rep-
resents a research area in need of further investigation.6,8
In a continuation of our long-standing interest in the
synthesis and structure–activity relationship (SAR) studies
of jaspine B, here we describe the development of a total
synthetic route to jaspine B, and further application of the
method in strategic structural modification studies of the
C2 and C4 substituents thereof (Scheme 1).
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l.Additionally, with a view to clarifying some conflicting
reports,6b,7k we have also reinvestigated a previously report-
ed jaspine B synthesis from our research9 (see below), and
the results of the study reported herein.
Soon after the isolation and biological activity of jaspine
B were reported, we undertook a preliminary study aimed
at the total synthesis of this bioactive natural product. The
retrosynthetic strategy for the intended synthesis envi-
sioned utilization of the L-serine-derived chiral amino-
butenolide 1 (Scheme 1), a previously developed ‘chiron’
from our research,10 as a strategic chiral platform towards
rapid construction of the all-syn 2,3,4-trisubstituted struc-
tural framework of jaspine B.
Thus, starting from aminobutenolide 1, a two-step reac-
tion sequence involving selective cleavage of the N,O-ace-
tonide linkage and exposure of the resulting N-Cbz-amino-
alcohol to mild basic conditions resulted in a clean and ste-
reoselective formation of the bicyclic lactone 2 (Scheme 2).
The stereochemistry at the newly formed chiral center is at-
tributable to the energetically favorable formation of the
cis-fused [5,5]-bicyclic ring junction. Attempting to install
the C14-alkyl chain as in the natural product, partial reduc-
tion of the lactone to lactol 3 and its subsequent condensa-
tion with a C12-alkyl donor Wittig reagent led to the olefin
derivative 4 as an E/Z-isomeric mixture. Interestingly,
during this reaction process, the secondary alkoxide ion (at
C3) generated in situ was found to collapse on the neigh-
boring carbamoyl moiety at C4, forming a skeletal rear-
ranged cyclic carbamate. Finally, hydrogenation of the ole-
fin providing the required C2-tetradecyl analogue 5, and al-
kaline cleavage of the cyclic carbamate culminated in the
purported synthesis of jaspine B.
Scheme 2  Our previous approach to jaspine B9
In the 2005 publication9 reporting the results of our
above synthesis, the stereochemistry of the final product
was assigned as the (expected) natural (2S,3S,4S) absolute
configuration. However, in a surprising development, a sub-
sequent study (2008)6c by Davies and co-workers revealed
that the product obtained during our above synthesis was
not the all-syn natural jaspine B as reported, but the corre-
sponding C2-epi analogue thereof. This reassignment of the
above stereochemistry was based on comparison of the
spectroscopic data of jaspine B and the C2-epimer, as avail-
able from several studies published subsequent to our re-
port.6c To rationalize the formation of this unexpected
product, Davies also suggested an alternative reaction path-
way, wherein the transient aldehyde intermediate 6 formed
in situ (Scheme 3) from the lactol 3 under the base-promot-
ed Wittig olefination conditions, could have undergone a
C2 epimerization via a retro-Michael–Michael addition se-
quence (in a β-elimination followed by recyclization pro-
cess), resulting in the sterically more favorable C2–C3
trans-tetrahydrofuran aldehyde intermediate 8.6c Subse-
quent transformations involving this (2R)-aldehyde 8 ulti-
mately led to the formation of 2-epi-jaspine B.
Scheme 3  C2-Epimerization: A plausible pathway (as suggested by 
Davies)6c
However, a more recent publication by Kim and co-
workers7k added further intrigue to the overall scenario re-
garding our synthesis of jaspine B reported above, and the
subsequent observations by Davis. In their study pursuing
the total synthesis of jaspine B and its 2-epi analogue, Kim’s
group utilized a phytosphingosine-derived common pre-
cursor I to selectively obtain either the all-syn-substituted
bicyclic oxazolidinone intermediate 5, or the corresponding
2-epi analogue 9 (Scheme 4) thereof.7k Subsequent oxazo-
lidinone ring cleavage led to jaspine B, or 2-epi-jaspine B,
respectively. Surprisingly however, upon comparing the
spectral data of the above oxazolidinones with the corre-
sponding intermediate from our previously reported syn-
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l.us was identical to the same intermediate from his study,
and is significantly different from that of the C2-epimeric
analogue 9. On the basis of this study, while confirming
Davies’ reported observation6c that the final product ob-
tained during our previous synthesis was indeed the 2-epi
analogue of jaspine B, Kim however reiterated that the bicy-
clic oxazolidinone intermediate 5 as reported by us does
contain the correct (2S,3S,4S) stereocenters and could not
have been a logical precursor to the 2-epi-jaspine B as ob-
tained.7k
Scheme 4  Kim’s synthesis of jaspine B and 2-epi-jaspine B7k
In view of these intriguing and apparently contradictory
observations, during the present research, we decided to
reinvestigate the synthetic route as employed during our
previous synthesis of jaspine B and try to identify the
source of any anomaly.
Accordingly, by following the same protocol used in our
initial synthesis (Scheme 1), starting from the bicyclic lac-
tone 2, we repeated the same synthetic sequence involving
DIBAL-H mediated reduction of the lactone to a lactol, its
Wittig olefination, hydrogenation of the resulting adduct,
and final hydrolytic cleavage of the cyclic carbamate. How-
ever, to our surprise, spectral and analytical data of the final
product thus obtained was found to be identical to the nat-
ural jaspine B stereoisomer, and not the 2-epi analogue
thereof. Similarly, the spectral data of the penultimate bicy-
clic oxazolidinone intermediate obtained during the syn-
thesis was also found to be consistent with the all-syn ste-
reoisomer 5. As the purported C2-epimerization in our pre-
vious synthesis of jaspine B was suggested to have taken
place under the basic reaction conditions of the Wittig ole-
fination (6 → 8; Scheme 2),6c we also repeated the above
synthetic sequence, this time performing the Wittig reac-
tion in the presence of an excess of base (5 equiv). However,
the penultimate bicyclic oxazolidinone 5, and the final jas-
pine B ultimately obtained from this effort were also found
to be the natural all-syn stereoisomers, and not the C2-epi-
meric analogues thereof. The above experiments indicate
that the epimeric jaspine B, as obtained during our previous
synthetic endeavor, could not have resulted from the sus-
pected base-mediated epimerization of the transient alde-
hyde intermediate 6.
The observations reported in Kim’s publication,7k and
our above reinvestigation involving the Wittig olefination
sequence, therefore confirmed that, whereas the final prod-
uct obtained from our initial synthesis is indeed 2-epi-jas-
pine B, the epimerization could not have been caused by
base/basic conditions of the Wittig reaction process.
In view of the above conclusion, we were curious to as-
certain whether, instead of base catalysis, a Lewis acid me-
diated epimerization11 during the lactone to lactol reduc-
tion step could have been responsible for the formation of a
C-2 epimeric aldehyde intermediate, which, in turn, led to
the C-2 epimeric jaspine B in our previous synthetic en-
deavor. We envisioned a probable mechanistic pathway,
wherein, during the lactone reduction process involving
this particular reaction batch, the adventitious presence of
a Lewis acidic contaminant derived from impure/partially
degraded DIBAL-H triggered a retro-Michael–Michael addi-
tion sequence involving the lactol-3 derived hydroxyalde-
hyde intermediate A (Scheme 5), resulting in the formation
of the sterically more favorable 2,3-trans-substituted C2-
epimeric aldehyde B as shown, and ultimately leading to 2-
epi-jaspine B.
Scheme 5  A Lewis acid mediated alternative C2-epimerization path-
way
As per the above rationalization, we reasoned that,
during our previous attempt at the synthesis of jaspine B,
the compound characterization data as reported for the bi-
cyclic oxazolidinone 5 could probably have been obtained
from an initial batch (standardization step) of reaction
product, wherein the use of fresh/non-contaminated
DIBAL-H as reducing agent avoided any C-2 epimerization.
However, in moving forward with the total synthesis en-
deavor, in the subsequent scaled-up version of the reaction,
possible use of improperly stored/degraded reagent result-
ed in the unforeseen formation of the epimeric aldehyde B,
and the consequently obtained 2-epi-jaspine B analogue.
To verify the above hypothesis, we investigated the fea-
sibility of Lewis acid mediated epimerization of lactol 3.
Unfortunately, as the original batches of DIBAL-H reagents
that were used during our initial synthetic endeavors have
long been exhausted, we are unable to determine the exact



































© Georg Thieme Verlag  Stuttgart · New York — Synthesis 2017, 49, 2088–2100
2091

































l.responsible for the purported lactol epimerization. As an
alternative, it was therefore decided to undertake the in-
tended investigation by utilizing representative Lewis acid-
ic reagents as available commercially. Accordingly, in sepa-
rate sets of experiments, lactol 3 was treated with either
BF3·Et2O or AlCl3 (0.5 M in THF). However, all of the above
epimerization attempts, employing a variety of reaction
conditions (varied reagent equivalence, reaction tempera-
ture, reaction time) proved unsuccessful, resulting either in
the recovery of the unchanged lactol 3 or decomposition of
the starting material to an intractable mixture of products.
Curiously, while the above experiments involving Lewis
acid catalysis did not lead to the epimerization of lactol 3,
the failure to effect epimerization of lactol 3 under basic
conditions (see below) is equally baffling. Therefore, at this
stage it will probably be premature to confirm (or disprove)
either of the proposed pathways that could have possibly
led to the epimeric jaspine B product during our initially re-
ported synthetic endeavor (Scheme 2). Evidently, more re-
search will have to be undertaken to elucidate the exact
mechanistic pathway responsible for the unforeseen forma-
tion of the above product.
Continuing with our interest in the synthesis and me-
dicinal chemical investigations of jaspine B, in the present
research, we have also developed a revised reaction strate-
gy towards circumventing any undesired C2-epimerization,
and achieving a flexible total synthesis route to the above
natural product and strategically designed analogues there-
of.
Thus, starting from our previously employed furofura-
none building block 2,9 exhaustive reduction of its lactone
functionality provided diol 10 in good yield (Scheme 6). Al-
though the above reduction could also be achieved by using
an excess of DIBAL-H alone, the recovery of the product diol
was found to be poor compared with the two-step se-
quence involving initial DIBAL-H (1.2 equiv) reduction of
the lactone to the corresponding lactol, followed by further
reduction of the crude reaction product with sodium boro-
hydride. Subsequent selective protection of the C3-C4 ami-
no alcohol functionalities as the oxazolidine 11, and con-
version of the free primary hydroxy group to the corre-
sponding tosylate provided the desired fully protected
compound 12 in good overall yield.
Towards installation of the required alkyl substituent at
C2, facile SN2 displacement of the tosylate group with a do-
decyl organocuprate reagent generated in situ as shown,
uneventfully provided the fully protected jaspine B deriva-
tive 13. Finally, global deprotection of 13 under acidic con-
ditions afforded the desired jaspine B as its hydrochloride
salt.
Structure–Activity Relationship Studies
Having developed an efficient route to jaspine B, further
utilization of the method towards SAR-targeted analogues
of this natural product was next undertaken.
C-2-Alkyl-Modified Analogues: Jaspine B has a long lipo-
philic alkyl chain at the C2-position. Although some of the
previous studies have targeted modification of this tetrade-
cyl side chain, there has been no systematic study attempt-
ing to relate optimum chain length and bioactivity. Accord-
ingly, we investigated the optimum chain length required
for biological activity. Thus, replacement of the tetradecyl
side chain of jaspine B with a shorter chain (propyl), a me-
dium chain (hexyl), and a benzylic functionality as a probe
for possible π–π interactions at the binding pocket, were
undertaken.
Syntheses of the target analogues were initiated by uti-
lizing the advanced intermediate 12 from our total synthet-
ic route. Thus, by following the same reaction protocol as in
the synthesis of jaspine B, displacement of tosylate 12 with
alkyl-magnesiocuprates generated in situ as shown, afford-
ed the corresponding C2-alkylated analogues 14a–c
(Scheme 7) in good yields. Subsequent one-pot removal of
both the protecting groups under acidic conditions provid-
ed the desired C2-alkyl chain modified analogues 15a–c as
hydrochloride salts.
Scheme 7  Syntheses of C2-alkyl analogues of jaspine B
C-2-Ether Analogues: The natural tetradecyl side chain
of jaspine B renders this molecule highly lipophilic
(CLogP = 6.21) and ‘non-drug-like’.12 Aiming to modulate
the lipophilicity of the above substituent, we investigated
analogues wherein a methylene group in the C2-alkyl chain
was subjected to bioisosteric replacement with a more po-
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l.lar oxygen functionality. It was reasoned that, in addition to
increased polarity of the intended analogues, the H-bond
acceptor oxygen atom in the side chain could also be a po-
tential site for binding interactions at the target-binding
pocket.
Accordingly, by utilizing the strategically protected tet-
rahydrofuran intermediate 11 from our total synthesis,
deprotonation of the primary hydroxyl group and subse-
quent O-alkylation with a representative set of three differ-
ent alkyl halides, led to the formation of the corresponding
ether analogues 16a–c (Scheme 8) in good yields. In a sub-
sequent two-step deprotection protocol, initial hydrolytic
cleavage of the oxazolidine ring providing the N-Cbz-pro-
tected amino alcohols 17a–c, followed by reductive remov-
al of the amine protecting group, provided the desired C2-
alkyloxyalkyl analogues 18a–c in good overall yields.
Scheme 8  Syntheses of C2-ether analogues of jaspine B
C-2-Alkylamine Analogues: In continued studies aimed
at modification of the lipophilic C2-alkyl chain of jaspine B,
bioisosteric replacement of one of the side chain methylene
groups with an amine (NH) moiety was next undertaken.
As with the ether analogues described above, it is expected
that, in addition to imparting increased hydrophilicity, the
amine moiety thus introduced in the side chain could also
provide a favorable tool towards probing potential H-bond
interactions (both as donor and acceptor) with appropriate
amino acid residues at the enzyme binding pocket.
Starting from the bicyclic lactol intermediate 3, the tar-
get analogues were synthesized by following a concise and
efficient protocol as described below. Subjecting lactol 3 to
standard reductive amination with a select set of primary
amines in the presence of sodium triacetoxyborohydride
provided the corresponding C2-alkylamino tetrahydrofuran
derivatives 19a–c (Scheme 9) in good yields.
Subsequent hydrolytic removal of the Cbz-protecting
group uneventfully resulted in the desired C2-alkylamine
substituted jaspine B analogues 20a–c as the corresponding
HCl salts.
C-4-Guanidine Analogue: Except for a surprisingly few
reports involving modification of the C4-amine of jaspine B,
there have been no SAR studies to determine the role of the
above amine in the biological activity of this cytotoxic natu-
ral product. We therefore carried out strategic modifica-
tions of the C4-amine and evaluated the effect on biological
activity.
In classical medicinal chemical approaches, guanidine
motifs are often introduced as strategic alternatives for
amine functional groups. In addition to strong H-bond
forming capabilities, the higher basicity and increased af-
finity for ionic interactions with appropriate counter anions
at enzyme binding pockets render the guanidine moiety a
preferred replacement for amine groups in bioactive mole-
cules. Thus, with the aim of probing or modulating the pos-
sible biological role of the C4-amine of jaspine B in ionic, or
salt-bridge forming binding interactions, we investigated
the synthesis of the corresponding C4-guanidine analogue
of jaspine B 22 (Scheme 10).
Thus, starting from jaspine B, as obtained from our total
synthesis, its reaction with a known guanidine transfer re-
agent13 under standard conditions cleanly provided the cor-
responding Boc-protected guanidine derivative 21 (Scheme
10). Removal of the Boc-protecting groups with trifluoro-
acetic acid resulted in the desired C4-guanidino jaspine B
analogue 22 (as the TFA salt).
Scheme 10  Synthesis of C4-guanidino jaspine B analogue
C4-Azide Analogue: Continuing with the investigation of
further modified analogues at the C4-position, conversion
of the C4-amine of jaspine B into a polar and linear azide
moiety was next undertaken. Accordingly, in a one-step
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l.azide resulted in a straightforward diazotransfer reaction
forming the desired C4-azido jaspine B analogue 23
(Scheme 11).
Scheme 11  Synthesis of C4-azido jaspine B analogue
C4-Triazole Analogues: Having an easy access to the C4-
azido jaspine B analogue from the above synthetic route
also created the opportunity to investigate replacement of
the amine group of jaspine B with a biologically relevant
triazole motif. Accordingly, installation of the target triazole
group at the C4-position of jaspine B was undertaken by
employing the known azide–alkyne cycloaddition proto-
col.14 Thus, subjecting azido analogue 23 to a standard Cu(I)
catalyzed 1,3-dipolar cycloaddition with 1-pentyne led to
the regioselective formation of the corresponding 4-(1,4-
disubstituted triazolo)jaspine B analogue 24 (Scheme 12).
Scheme 12  Syntheses of C4-triazolo jaspine B analogues
Similarly, by employing Fokin’s method,15 1,3-dipolar
cycloaddition of the azide 23 with 1-butyne in the presence
of catalytic RuCp*Cl(PPh3)2 afforded the regioisomeric 4-
(1,5-disubstituted triazolo)jaspine B analogue 25 (Scheme
12).
To determine the effects of the described structural
modifications on cytotoxic activity, all 13 jaspine B ana-
logues synthesized during the present study were evaluat-
ed against murine B16 melanoma cells. Jaspine B obtained
from the present total synthetic route was also included as
a reference in this assay (see the experimental section for
assay details). As seen from Table 1, the synthetic jaspine B
exhibited a dose-dependent cytotoxicity comparable to
that of the natural product (IC50 = 0.56 μM),3 whereas, in an
interesting trend, it was observed that shortening of the
tetradecyl side chain of the natural product to a hexyl ana-
logue (15b) retained substantial activity; further shorten-
ing to a propyl side chain (15a), or incorporation of a ben-
zylic moiety (15c) resulted in significant loss of activity.
Table 1  Evaluation of Cytotoxic Activities of Jaspine B and Analogues 
against Murine B16 Melanoma Cells
Notably, the CLogP value (1.979)16 of the C2-hexyl ana-
logue 15b indicates a substantial improvement in its hydro-
philic character compared with that of the parent jaspine B
(CLogP 6.21). In the C2-ether series involving bioisosteric
replacement of an internal methylene group with oxygen,
the long chain alkyloxy analogue 18b retained substantial
activity, while also improving the hydrophilicity (CLogP
4.81) to a reasonable extent. However, the corresponding
shorter chain (18a), or the benzyloxy (18c) analogues were
devoid of cytotoxic activity. Similarly, in the C2-alkylamine
series, the long chain alkyl amine derivative 20b is among
the most active analogues synthesized, with significantly
improved hydrophilic character (CLogP 3.47) compared
with jaspine B. The other congeners in this series (20a and
20c) were however inactive. Modification of the C4-amine
of jaspine B to the corresponding guanidine analogue 22 re-
sulted in an analogue with partially retained activity,
whereas the C4-azide (23) and triazole-modified analogues
(24 and 25) were inactive.
The above results indicate that the highly lipophilic C2-
tetradecyl side-chain of jaspine B is not necessarily an es-
sential requirement for biological activity. Its replacement
with a somewhat shorter C2-alkyl substituent, or bio-
isosteric incorporation of more polar entities in the chain,
could provide a strategic means of obtaining jaspine B ana-
logues with improved ‘drug-like’ characteristics. However,
the C4-amine group of this natural product appears to play
an important role in its cytotoxic activity, and is apparently
intolerant of any modifications.
In conclusion, an efficient and practical total synthetic
route to jaspine B has been developed during the present
research. Flexibility of the above method towards strategic
structural modifications has also provided easy access to a
number of unique jaspine B analogues, allowing hitherto
unreported SAR investigations. The studies also demon-
strated a viable strategy towards modification of the highly
lipophilic C2-alkyl chain of the parent natural product to
more polar (hydrophilic) analogues with improved ‘drug-
like’ characteristics. The results from these studies are ex-
pected to provide useful directions towards the future de-



































Entry Compound IC50 (μM) Entry Compound IC50 (μM)
1 jaspine B 0.56  8 20a >25
2 15a >25  9 20b  1.7
3 15b 3.3 10 20c >25
4 15c >25 11 22  10.1
5 18a >25 12 23 >25
6 18b 2.04 13 24 >25
7 18c >25 14 25 >25© Georg Thieme Verlag  Stuttgart · New York — Synthesis 2017, 49, 2088–2100
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l.on the jaspine B structural lead. Simultaneously to the
above studies, a previously reported synthetic route to jas-
pine B from our group has also been reinvestigated to help
clarify some conflicting stereochemical issues. Although
the exact mechanistic pathway leading to the formation of
an unexpected epimeric product during our previous syn-
thetic endeavor remains unclear, the above reinvestigation
has confirmed the utility of our initially reported route in
the stereoselective synthesis of enantiopure natural jaspine
B.
All of the solvents and reagents used were obtained commercially and
used as such unless noted otherwise. Moisture- or air-sensitive reac-
tions were conducted under argon atmosphere in oven-dried (120 °C)
glass apparatus. Diethyl ether and THF were distilled from sodium
benzophenone ketyl, and dichloromethane was distilled over calcium
hydride, prior to use. Solvents were removed under reduced pressure
by using standard rotary evaporators. Flash column chromatography
was carried out using Silica gel 60 (230–400 mesh), while thin-layer
chromatography (tlc) was carried out on Silica Gel HLF, precoated
glass plates. All yields reported refer to isolated material judged to be
homogeneous by TLC and NMR spectroscopy. Optical rotations (at
589 nm) were measured at r.t. with an AUTOPOL IV Model automatic
polarimeter. A Shimadzu FTIR-8400S instrument was used to record
IR spectra. 1H and 13C NMR spectra were recorded with Bruker DRX
400 MHz, Bruker DRX 500 MHz, or Avance AV-III 500 MHz spectrom-
eters. Unless noted otherwise, NMR spectra were recorded with the
chemical shifts (δ) reported in ppm relative to Me4Si (for 1H) and
CDCl3 (for 13C) as internal standards, respectively. Mass spectra were
obtained with a ZAB HS mass spectrometer (VG Analytical Ltd., Man-
chester, U.K.) equipped with a 11/250 data system. Fast-atom bom-
bardment mass spectrometry (FAB-MS) experiments were performed
with a Xenon gun operated at 8 KeV energy and 0.8 mA emission.
Fast-atom bombardment high-resolution mass spectra [FAB-HRMS
(ESI-TOF)] were recorded at 1:10,000 resolution analyzer mode
(MCA). High-resolution mass spectrometry (HRMS) and FAB spectra
were obtained either with a VG instrument ZAB double-focusing
mass spectrometer, or with a LCT Premier Spectrometer.
(2S,3S,4S)-4-N-Benzyloxycarbonyl-3-hydroxy-4-(2-hydroxyeth-
yl)tetrahydrofuran (10)
Step 1: To a stirred solution of bicyclic lactone 29 (1.5 g, 5.4 mmol) in
anhydrous dichloromethane (25 mL) at –78 °C, was added DIBAL-H
(1 M in toluene, 6.5 mL, 6.5 mmol) dropwise over 10 min. After stir-
ring for another 1.5 h at the same temperature, the reaction was
quenched by adding MeOH (1.5 mL) and allowed to attain r.t. To the
resulting solution, EtOAc (40 mL) and saturated aq sodium potassium
tartarate (10 mL) were added and the mixture was stirred for 1 h. The
organic layer was separated, and the aqueous layer was extracted
with EtOAc (3 × 25 mL). The combined extract was dried over anhy-
drous Na2SO4, filtered, and the filtrate was concentrated on a rotary
evaporator to obtain the crude product (1.55 g), which was used as
such for the next reaction.
Step 2: The product from step 1 (1.5 g) was dissolved in EtOH (20 mL),
the solution was cooled to 0 °C (ice-bath) and powdered NaBH4 (420
mg, 11.11 mmol) added in small portions over a period of 5 min. After
stirring at 0 °C for 15 min, the reaction was quenched by adding
crushed ice and the resulting mixture was extracted thoroughly with
EtOAc (8 × 30 mL). The combined extract was dried (anhyd. Na2SO4),
filtered, concentrated, and the residue was purified by column chro-
matography (hexanes/EtOAc, 1:1 to 1:2) to afford the pure diol 10.
Yield: 1.2 g (77% over two steps); white solid; mp 105–107 °C; [α]D
14.4 (c 0.4, CH3OH).
1H NMR (500 MHz, CDCl3): δ = 1.71–2.10 (m, 2 H), 2.25 (br s, 1 H,
exch. D2O), 3.37 (br s, 1 H, exch. with D2O), 3.66 (t, J = 10 Hz, 1 H),
3.67–3.75 (m, 1 H), 3.85–3.95 (br s, 1 H), 3.96–4.12 (m, 2 H), 4.21 (s,
1 H), 4.35–4.50 (m, 1 H), 5.12 (s, 2 H), 5.53 (br s, 1 H, exch. D2O), 7.30–
7.45 (m, 5 H).
13C NMR (125.8 MHz, CDCl3): δ = 31.2, 53.9, 59.5, 66.9, 69.9, 71.4,
81.9, 128.1, 128.2, 128.6, 136.3, 158.0.




An ice-cooled mixture of diol 10 (2 g, 7.1 mmol), 3-pentanone (12
mL), and freshly prepared 3,3-dimethoxypentane17 (20 mL) was treat-
ed with a catalytic amount of BF3·OEt2 (0.1 mL). After stirring the re-
sulting solution at the same temperature for 3 h, the reaction was
quenched with triethylamine (0.5 mL) and concentrated under vacu-
um. The crude residue was purified by flash chromatography (hex-
anes/EtOAc, 4:1 to 1:1), to afford the corresponding oxazolidine de-
rivative 11.
Yield: 2 g (81%); light-yellow viscous liquid; [α]D 71.1 (c 1.8, CH2Cl2).
1H NMR (500 MHz, CDCl3): δ (mixture of rotamers) = 0.71–0.92 (m,
6 H), 1.66–2.21 (m, 7 H), 3.55–3.73 (m, 2 H), 3.74–3.91 (m, 2 H), 4.01
and 4.18 (2 × m, 1 H), 4.41–4.71 (m, 2 H), 5.05–5.21 (m, 2 H), 7.25–
7.45 (m, 5 H).
13C NMR (125.8 MHz, CDCl3): δ (mixture of rotamers) = 7.4, 8.1, 29.3,
29.6, 30.3, 30.8, 30.9, 31.0, 60.7, 60.8, 62.8, 64.0, 66.7, 67.4, 73.3, 73.8,
80.9, 81.5, 81.9, 82.0, 101.6, 102.4, 127.7, 128.0, 128.1, 128.2, 128.6,
136.1, 136.5, 151.6, 152.9.




To an ice-cooled solution of the oxazolidine alcohol 11 (2 g, 5.73
mmol) in anhydrous dichloromethane (30 mL) were added p-toluene-
sulfonyl chloride (9.85 g, 9 mmol), pyridine (0.9 mL, 11.1 mmol), and
a catalytic amount of 4-DMAP (30 mg). After stirring the resulting
solution at r.t. for 48 h, the reaction was quenched with 10% aq HCl
(50 mL). The organic layer was separated, and the aqueous layer was
extracted with dichloromethane (50 mL). The combined organic ex-
tract was washed with brine (50 mL), dried over anhydrous Na2SO4,
filtered, and concentrated under vacuum. Purification of the crude
residue by flash chromatography (hexanes/EtOAc, 4:1 to 2:1) afforded
the pure tosylate 12.
Yield: 2.6 g (90%); light-yellow viscous liquid; [α]D 48.8 (c 0.62,
CH2Cl2).
1H NMR (400 MHz, CDCl3): δ (mixture of rotamers) = 0.73–0.90 (m,
6 H), 1.61–2.21 (m, 6 H), 2.47 (s, 3 H), 3.41–3.60 (m, 2 H), 3.94 and
4.21 (2 × d, J = 8.2 Hz and 10.0 Hz, 1 H), 4.14–4.29 (m, 2 H), 4.46–4.60
(m, 2 H), 5.05–5.21 (m, 2 H), 7.31–7.43 (m, 7 H), 7.81 (d, J = 8.24 Hz,
2 H).© Georg Thieme Verlag  Stuttgart · New York — Synthesis 2017, 49, 2088–2100
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l.13C NMR (125.8 MHz, CDCl3): δ = 7.4, 8.0, 21.6, 28.0, 29.1, 29.6, 30.1,
30.9, 63.0, 64.1, 66.7, 67.4, 68.0, 73.1, 73.7, 80.7, 101.5, 102.3, 127.7,
127.9, 128.0, 128.1, 128.2, 128.4, 128.6, 130.0, 132.9, 136.1, 136.5,
144.8, 151.6, 152.9.




To a cooled mixture (–78 °C) of tosylate 12 (250 mg, 0.5 mmol) and
finely powdered CuI (190 mg, 1 mmol) in anhydrous THF (8 mL) was
added dodecylmagnesiumbromide (1 M in Et2O, 3.4 mL, 3.4 mmol)
dropwise over a period of 10 min. After stirring at –78 °C for 30 min,
the reaction mixture was warmed to 0 °C (ice-bath) and stirring was
continued for 1.5 h. The reaction was quenched with sat. NH4Cl (5
mL) and extracted with EtOAc (5 × 25 mL). The combined extract
washed sequentially with water and brine, dried over anhydrous
Na2SO4, filtered, and the solvent was removed under vacuum. Purifi-
cation of the crude residue by flash chromatography (hexanes/EtOAc,
9:1) afforded the fully protected jaspine B derivative 13.
Yield: 180 mg (72%); light-yellow viscous liquid; [α]D 65.7 (c 0.6,
CH2Cl2).
1H NMR (500 MHz, CDCl3): δ (mixture of rotamers) = 0.81–0.95 (m,
9 H), 1.15–1.48 (m, 24 H), 1.71–1.97 (m, 5 H), 1.98–2.19 (m, 1 H),
3.34–3.44 (m, 1 H), 3.54–3.70 (m, 1 H), 4.01 and 4.09 (2 × d, J =
10.5 Hz and 10.7 Hz, 1 H),4.50–4.56 (2 × s, 2 H), 5.06–5.22 (m, 2 H),
7.30–7.46 (m, 5 H).
13C NMR (125.8 MHz, CDCl3): δ (mixture of rotamers) = 7.4, 8.1, 14.1,
22.7, 26.3, 28.1, 29.4, 29.5, 29.6, 29.7, 31.9, 63.0, 64.1, 66.6, 67.4, 73.0,
73.6, 80.5, 81.1, 83.4, 83.5, 101.3, 102.1, 127.7, 128.0, 128.1, 128.2,
128.5, 128.6, 136.2, 136.6, 151.7, 153.0.
HRMS (ESI): m/z [M + H]+ calcd for C31H52NO4: 502.3896; found:
502.3846.
Jaspine B Hydrochloride
A solution of the N,O-protected jaspine B derivative 13 (85 mg, 0.169
mmol) in 50% aq HCl (10 mL) was heated at reflux for 16 h. The reac-
tion mixture was cooled to r.t. and extracted with Et2O (10 mL) to re-
move any organic soluble impurities. The aqueous layer was then
concentrated in a rotary evaporator and the residual oily liquid was
kept under high vacuum overnight to afford the desired jaspine B hy-
drochloride salt.
Yield: 44 mg (77%); white solid; [α]D 2.5 (c 0.46, CH3OH).
1H NMR (400 MHz, CD3OD): δ = 0.88 (t, J = 5.6 Hz, 3 H), 1.20–1.51 (m,
24 H), 1.57–1.72 (m, 2 H), 3.66–3.73 (m, 1 H), 3.75–3.83 (m, 1 H),
3.84–3.95 (m, 2 H), 4.25 (br s, 1 H).
13C NMR (125.8 MHz, CD3OD): δ = 14.4, 23.8, 29.7, 30.5, 30.7, 30.8,
30.9, 33.1, 54.1, 69.0, 71.0, 84.4.
HRMS (ESI): m/z [M + H]+ calcd for C18H38NO2: 300.2903; found:
300.2879.
N,O-Protected C2-Alkyl Analogues 14a–c; General Procedure
To a cooled mixture (–78 °C) of tosylate 12 (1 equiv) and finely pow-
dered CuI (2 equiv) in anhydrous THF (8 mL) was added the respective
Grignard reagent (7 equiv) dropwise over a period of 10 min. After
stirring at –78 °C for 30 min, the reaction mixture was warmed to
0 °C (ice-bath) and stirring was continued for 12–16 h (monitoring by
TLC). Subsequently, the reaction was quenched with sat. NH4Cl (5 mL)
and extracted with EtOAc (5 × 25 mL). The combined extract was
washed sequentially with water and brine, dried over anhydrous
Na2SO4, filtered, and the solvent was removed under vacuum. Purifi-
cation of the crude residue by flash chromatography (hexanes/EtOAc,
9:1) afforded the corresponding C2-alkyl analogues 14a–c.
(3aS,6S,6aS)-Benzyl 2,2-Diethyl-6-propyltetrahydrofuro[3,4-d]ox-
azole-3(2H)-carboxylate (14a)
Yield: 72 mg (82%); light-yellow viscous liquid; [α]D 90.0 (c 1.1,
CH2Cl2).
1H NMR (500 MHz, CDCl3): δ (mixture of rotamers) = 0.81–0.91 (m,
6 H), 0.95–1.01 (m, 3 H), 1.41–1.54 (m, 2 H), 1.71–2.07 (m, 6 H), 3.38–
3.45 (m, 1 H), 3.59–3.69 (m, 1 H), 3.98–4.05 (m, 0.6 H), 4.06–4.15 (m,
0.4 H), 4.45–4.51 (m, 0.6 H), 4.53–4.61 (m, 1.4 H), 5.11–5.21 (m, 2 H),
7.21–7.41 (m, 5 H).
13C NMR (125.8 MHz, CDCl3): δ (mixture of rotamers) = 7.4, 8.07, 8.08,
14.3, 19.6, 29.3, 29.5, 30.1, 30.2, 30.3, 30.9, 62.9, 64.1, 66.6, 67.3, 73.0,
73.5, 80.5, 83.1, 83.2, 101.3, 102.0, 127.6, 128.0, 128.1, 128.5, 128.6,
136.1, 136.6, 151.6, 152.9.




Yield: 63 mg (66%); light-yellow viscous liquid; [α]D 82.3 (c 0.85,
CH2Cl2).
1H NMR (400 MHz, CDCl3): δ (mixture of rotamers) = 0.71–0.95 (m,
9 H), 1.23–1.49 (m, 8 H), 1.70–2.40 (m, 6 H), 3.31–3.42 (m, 1 H), 3.51–
3.71 (m, 1 H), 3.91–4.01 (m, 0.6 H), 4.11–4.81 (m, 0.4 H), 4.49–4.51
(m, 0.6 H), 4.53–4.61 (m, 1.4 H), 5.11–5.21 (m, 2 H), 7.29–7.41 (m,
5 H).
13C NMR (125.8 MHz, CDCl3): δ (mixture of rotamers) = 7.4, 8.1, 14.1,
22.5, 26.3, 28.1, 29.3, 29.4, 29.5, 29.7, 30.3, 30.9, 31.7, 62.9, 64.1, 66.6,
67.3, 73.0, 73.5, 80.5, 81.1, 83.4, 101.3, 102.0, 127.6, 128.0, 128.1,
128.4, 128.5, 136.2, 136.6, 151.6, 152.9.




Yield: 63 mg (75%); light-yellow viscous liquid; [α]D 88.4 (c 0.57,
CH2Cl2).
1H NMR (400 MHz, CDCl3): δ (mixture of rotamers) = 0.75–0.91 (m,
6 H), 1.71–1.91 (m, 7 H), 1.93–2.15 (m, 1 H), 2.61–2.78 (m, 2 H), 3.35–
3.48 (m, 1 H), 3.55–3.71 (m, 1 H), 3.96–4.05 (m, 0.6 H), 4.11–4.18 (m,
0.4 H), 4.45–4.51 (m, 0.6 H), 4.51–4.62 (m, 1.4 H), 5.11–5.22 (m, 2 H),
7.12–7.31 (m, 10 H).
13C NMR (125.8 MHz, CDCl3): δ (mixture of rotamers) = 7.4, 7.9, 8.1,
27.7, 27.8, 27.9, 28.1,, 28.7, 29.0, 29.4, 29.5, 29.7, 30.3, 30.8, 35.8, 35.9,
62.9, 64.1, 65.2, 66.6, 67.3, 73.0, 73.6, 80.5, 81.1, 83.2, 83.2, 101.3,
102.1, 125.7, 125.9, 126.1, 126.9, 127.2, 127.5, 127.8, 127.9, 128.0,
128.1, 128.2, 128.3, 128.4, 128.5, 128.6, 128.7, 129.3, 129.5, 130.5,
136.1, 136.6, 142.2, 151.6, 152.9.
HRMS (ESI): m/z [M + H]+ calcd for C26H34NO4: 424.2488; found:
424.2492.© Georg Thieme Verlag  Stuttgart · New York — Synthesis 2017, 49, 2088–2100
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l.C2-Alkyl Analogues 15a–c; General Deprotection Procedure
The N,O-protected C2-alkyl analogues 14a–c were heated at reflux in
a solution of 50% aq HCl for 12–16 h (monitored by TLC). The reaction
mixture was cooled to r.t. and extracted with dichloromethane (10
mL) to remove any organic soluble impurities. The aqueous layer was
then concentrated in a rotary evaporator and the residual oily liquid
was kept under high vacuum overnight to afford the desired jaspine B
C2 alkyl analogues 15a–c as their hydrochloride salts.
(2S,3S,4S)-4-Amino-2-propyltetrahydrofuran-3-ol Hydrochloride 
(15a)
Yield: 31 mg (82%); colorless hygroscopic solid; [α]D 7.7 (c 0.6,
CH3OH).
1H NMR (500 MHz, CD3OD): δ = 0.95–1.05 (m, 3 H), 1.41–1.59 (m,
2 H), 1.61–1.72 (m, 2 H), 3.72–3.79 (m, 1 H), 3.81–3.88 (m, 1 H), 3.89–
3.98 (m, 2 H), 4.29 (br s, 1 H).
13C NMR (125.8 MHz, CD3OD): δ = 12.3, 18.2, 28.6, 52.1, 66.7, 68.6,
81.8.




Yield: 35 mg (83%); colorless hygroscopic solid; [α]D 5.4 (c 1.35,
CH3OH).
1H NMR (500 MHz, CD3OD): δ = 0.76–0.89 (m, 3 H), 1.19–1.41 (m,
8 H), 1.51–1.64 (m, 2 H), 3.59–3.67 (m, 1 H), 3.68–3.77 (m, 1 H), 3.78–
3.91 (m, 2 H), 4.15–4.21 (m, 1 H).
13C NMR (125.8 MHz, CD3OD): δ = 13.3, 22.5, 26.0, 28.6, 29.4, 31.8,
53.2, 67.8, 69.7, 83.2.




Yield: 60 mg (90%); light-yellow hygroscopic solid; [α]D 10.4 (c 0.86,
CH3OH).
1H NMR (500 MHz, CD3OD): δ = 1.61–1.94 (m, 4 H), 2.61–2.81 (m,
2 H), 3.75–4.11 (m, 4 H), 4.21–4.41 (m, 1 H), 7.09–7.39 (m, 5 H).
13C NMR (125.8 MHz, CD3OD): δ = 29.1, 29.3, 36.9, 54.3, 69.0, 70.8,
84.2, 126.7, 129.3, 129.4, 129.7, 143.5.
HRMS (ESI): m/z [M + H]+ calcd for C13H20NO2: 222.1494; found:
222.1475.
Carboxylates 16a–c; General O-Alkylation Procedure
To an ice-cooled solution of the oxazolidine alcohol 11 (1 equiv) in
THF (10% solution w/v) was added potassium tert-butoxide (1 M in
THF, 3 equiv) and the solution was stirred for 30 min. The respective
alkyl halides (1.2 equiv) were then added to the ice-cooled solution
with stirring. The reaction mixture was allowed to attain r.t. and
stirred for 6–16 h (tlc monitoring). The reaction was quenched with
sat. aq NH4Cl and extracted with EtOAc (3×). The combined extract
was washed with brine and dried over anhydrous Na2SO4. Removal of
solvent under vacuum and purification of the residue by flash chro-




Yield: 75 mg (82%); light-yellow syrupy liquid; [α]D 79.3 (c 0.38,
CHCl3).
1H NMR (500 MHz, CDCl3): δ (mixture of rotamers) = 0.75–0.98  (m,
6 H), 1.15–1.21 (m, 3 H), 1.69–1.99 (m, 3 H), 2.01–2.15 (m, 3 H), 3.45–
3.51 (m, 2 H), 3.55–3.68 (m, 4 H), 3.95–4.03 (m, 0.6 H), 4.09–4.18 (m,
0.4 H), 4.45–4.63 (m, 2 H), 5.09–5.21 (m, 2 H), 7.29–7.41 (m, 5 H).
13C NMR (125.8 MHz, CDCl3): δ (mixture of rotamers) = 7.3, 7.4, 8.1,
15.2, 28.5, 29.2, 29.6, 29.7, 30.2, 30.9, 63.0, 64.1, 66.1, 66.6, 67.3, 67.4,
67.5, 73.0, 73.6, 80.2, 80.6, 81.2, 101.3, 102.1, 127.6, 128.0, 128.5,
136.1, 136.6, 151.6, 152.9.




Yield: 70 mg (68%); light-yellow viscous liquid; [α]D 59.3 (c 0.67,
CHCl3).
1H NMR (500 MHz, CDCl3): δ (mixture of rotamers) = 0.81–0.95 (m,
9 H), 1.21–1.41 (m, 20 H), 1.71–2.01 (m, 3 H), 1.95–2.19 (m, 3 H),
3.35–3.51 (m, 2 H), 3.51–3.71 (m, 4 H), 3.95–4.05 (m, 0.6 H), 4.11–
4.15 (m, 0.4 H), 4.49–4.53 (m, 0.6 H), 4.55–4.63 (m, 1.4 H), 5.09–5.21
(m, 2 H), 7.29–7.41 (m, 5 H).
13C NMR (125.8 MHz, CDCl3): δ (mixture of rotamers) = 7.4, 8.1, 14.1,
22.7, 25.8, 26.2, 28.5, 29.2, 29.3, 29.4, 29.5, 29.6, 29.7, 30.0, 30.3, 30.9,
31.9, 32.8, 63.0, 64.2, 66.7, 67.4, 67.6, 67.7, 71.0, 71.1, 73.0, 73.6, 80.3,
80.6, 81.2, 101.3, 102.1, 127.7, 128.0, 128.1, 128.5, 128.6, 136.2, 136.6,
151.6, 152.9.




Yield: 120 mg (69%); light-yellow viscous liquid; [α]D 40.4 (c 0.55,
CH2Cl2).
1H NMR (500 MHz, CDCl3): δ (mixture or rotamers) = 0.78–0.83 (m,
3 H), 0.86–0.91 (m, 3 H), 1.71–2.11 (m, 4 H), 2.14–2.18 (m, 3 H), 3.58–
3.69 (m, 3 H), 3.98–4.12 (m, 0.6 H), 4.13–4.16 (m, 0.4 H), 4.45–4.55
(m, 3 H), 4.56–4.59 (m, 1 H), 5.11–5.21 (m, 2 H), 7.29–7.39 (m, 10 H).
13C NMR (125.8 MHz, CDCl3): δ (mixture or rotamers) = 7.4, 8.1, 25.6,
28.5, 29.3, 29.6, 30.3, 31.0, 61.1, 63.0, 64.2, 66.6, 67.3, 67.4, 67.9, 72.9,
73.0, 80.3, 80.6, 81.1, 101.3, 102.1, 127.5, 127.6, 128.1, 28.3, 128.5,
128.6, 136.1, 136.6, 138.4, 151.6, 152.9.
HRMS (ESI): m/z [M + H]+ calcd for C26H34NO5: 440.2437; found:
440.2433.
Carbamates 17a–c; General Acetonide Deprotection Procedure
An ice-cooled solution of TFA/H2O (excess) was added to the N,O-ox-
azolidine C2-alkyloxy analogues 16a–c and stirred at r.t. for 3–4 h.
Upon completion of reaction (monitored by TLC), the reaction mix-
ture was neutralized by cautiously pouring into a saturated solution
of NaHCO3. The resulting solution was extracted thoroughly with
chloroform (5×). The combined organic extract washed with brine,
dried over anhydrous Na2SO4, and filtered. Removal of solvent under
vacuum and purification of the residue by flash chromatography af-
forded the acetonide deprotected C2-ether analogues 17a–c.© Georg Thieme Verlag  Stuttgart · New York — Synthesis 2017, 49, 2088–2100
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Yield: 48 mg (78%); white solid; mp 90–92 °C; [α]D 13.4 (c 0.55,
CDCl3).
1H NMR (500 MHz, CDCl3): δ = 1.11–1.31 (m, 3 H), 1.81–1.99 (m, 1 H),
2.01–2.21 (m, 1 H), 3.31–3.40 (m, 1 H), 3.41–3.58 (m, 2 H), 3.61–3.71
(m, 2 H), 3.84 (s, 1 H), 3.91–4.0 (m, 1 H), 4.01–4.09 (m, 1 H), 4.14 (s,
1 H), 4.31–4.48 (m, 1 H), 5.01–5.21 (m, 2 H), 5.51–5.65 (m, 1 H), 7.29–
7.48 (m, 5 H).
13C NMR (125.8 MHz, CDCl3): δ = 15.0, 29.9, 53.8, 66.7, 66.8, 66.9,
69.9, 71.1, 82.1, 128.1, 128.5, 136.4, 156.2.




Yield: 50 mg (76%); white fluffy solid; mp 121–124 °C; [α]D 7.7 (c
0.45, CHCl3).
1H NMR (400 MHz, CDCl3): δ = 0.85–0.95 (m, 3 H), 1.21–1.41 (m,
20 H), 1.81–1.95 (m, 1 H), 2.05–2.21 (m, 1 H), 3.33–3.51 (m, 3 H),
3.55–3.68 (m, 2 H), 3.87 (s, 1 H), 3.91–4.01 (m, 1 H), 4.02–4.09 (m,
1 H), 4.11–4.18 (m, 1 H), 4.31–4.48 (m, 1 H), 5.14 (s, 2 H), 5.51–5.61
(m, 1 H), 7.25–7.45 (m, 5 H).
13C NMR (125.8 MHz, CDCl3): δ = 14.1, 22.7, 26.1, 29.3, 29.4, 29.5,
29.6, 29.7, 29.9, 31.9, 53.9, 66.8, 67.0, 70.0, 70.3, 71.1, 71.8, 82.2,
128.1, 128.5, 136.5, 156.2.




Yield: 55 mg (85%); white solid; mp 136–137 °C; [α]D 5.6 (c 0.52,
CHCl3).
1H NMR (400 MHz, CDCl3): δ = 1.89–2.02 (m, 1 H), 2.05–2.21 (m, 1 H),
3.47–3.77 (m, 4 H), 3.91–4.09 (m, 2 H), 4.11–4.21 (m, 1 H), 4.31–4.45
(m, 1 H), 4.51–4.61 (m, 2 H), 5.13 (br s, 2 H), 5.51–5.61 (m, 1 H), 7.21–
7.41 (m, 10 H).
13C NMR (125.8 MHz, CDCl3): δ = 14.1, 14.2, 21.0, 50.8, 54.2, 60.4,
66.7, 66.8, 69.9, 71.1, 73.7, 81.9, 127.6, 127.8, 128.1, 128.4, 128.5,
128.6, 136.4, 137.1, 156.2.
HRMS (ESI): m/z [M + H]+ calcd for C21H26NO5: 372.1811; found:
372.1805.
Jaspine B C2-Ether Analogues 18a–c; General Hydrogenolysis Pro-
cedure
The N-Cbz-protected analogues 17a–c were dissolved in MeOH (1%
solution w/v) and 10% Pd-C (10% wt) was added. The reaction mix-
ture was flushed with hydrogen (twice), and stirred under a hydro-
gen atmosphere for 3–10 h (monitored by TLC). The reaction mixture
was filtered through a Celite pad and the residue was washed with
MeOH (3×). Removal of the combined filtrate under vacuum, and sub-
jecting the residue to overnight drying under high vacuum provided
the corresponding pure products 18a–c, respectively.
(2S,3S,4S)-4-Amino-2-(2-ethoxyethyl)tetrahydrofuran-3-ol (18a)
Yield: 20 mg (89%); colorless viscous liquid; [α]D 8.2 (c 1.15, CH3OH).
1H NMR (400 MHz, CD3OD): δ = 1.05–1.21 (m, 3 H), 1.73–1.91 (m,
2 H), 3.31–3.61 (m, 6 H), 3.79–3.87 (m, 2 H), 3.88–3.99 (m, 1 H).
13C NMR (125.8 MHz, CD3OD): δ = 15.4, 31.1, 56.0, 66.0, 67.3, 68.5,
72.1, 73.5, 81.4.




Yield: 25 mg (89%); colorless viscous liquid; [α]D 8.8 (c 0.54, CH3OH).
1H NMR (400 MHz, CD3OD): δ = 0.81–0.92 (m, 3 H), 1.21–1.41 (m,
18 H), 1.51–1.61 (m, 2 H), 1.82–1.98 (m, 2 H), 3.33–3.46 (m, 2 H),
3.52–3.60 (m, 2 H), 3.75–3.95 (m, 4 H), 4.22–4.30 (m, 1 H).
13C NMR (125.8 MHz, CD3OD): δ = 11.7, 21.0, 24.6, 27.6, 27.8, 27.9,
28.0, 30.4, 51.7, 66.0, 66.4, 68.4, 69.5, 79.0.




Yield: 21 mg (82%); light-yellow viscous liquid; [α]D 9.6 (c 1.2,
CH3OH).
1H NMR (500 MHz, CD3OD): δ = 1.81–2.11 (m, 2 H), 3.38–3.46 (m,
1 H), 3.48–3.55 (m, 1 H), 3.58–3.78 (m, 2 H), 3.81–3.93 (m, 2 H), 3.96–
4.04 (m, 1 H), 4.45–4.55 (m, 2 H), 7.21–7.30 (m, 1 H), 7.31–7.38 (m,
4 H).
13C NMR (125.8 MHz, CD3OD): δ = 27.0, 53.3, 65.7, 69.5, 70.8, 71.3,
71.7, 78.7, 126.0, 126.2, 126.7, 137.0.
HRMS (ESI): m/z [M + H]+ calcd for C13H20NO3: 238.1443; found:
238.1441.
C2-Alkylamine Analogues 19a–c; General Reductive Amination 
Procedure
To a stirred, ice-cooled solution of the bicyclic lactol 3 (1 equiv) in an-
hydrous THF (10% solution w/v) was added NaBH(OAc)3 (1.2 equiv)
followed by the respective alkyl amines (1 equiv). The reaction mix-
ture was allowed to attain r.t. and stirring was continued for 2–3 h.
Upon completion of the reaction (monitored by TLC), the reaction
mixture was quenched with sat. aq NaHCO3 solution and extracted
with EtOAc. The aqueous layer was saturated with solid NaCl and re-
extracted with EtOAc (2×). The combined extracts were washed se-
quentially with water and brine, and dried over anhydrous Na2SO4.
Solvent was removed under vacuum, and the crude product was puri-
fied by flash chromatography (MeOH/CH2Cl2+0.1% NH4OH, 5:95) af-




Yield: 50%; light-brown solid; mp 113–114 °C; [α]D 18 (c 0.5, CHCl3).
1H NMR (500 MHz, CDCl3): δ = 0.85–0.94 (m, 3 H), 1.31–1.41 (m, 2 H),
1.42–1.50 (m, 2 H), 1.81–2.04 (m, 3 H), 2.51–2.75 (m, 3 H), 2.85–2.94
(m, 1 H), 3.61–3.70 (m, 1 H),3.99–4.02 (m, 1 H), 4.03–4.12 (m, 2 H),
4.31–4.45 (m, 1 H), 5.11 (br s, 2 H), 5.61–5.71 (m, 1 H), 7.27–7.49 (m,
5 H).
13C NMR (125.8 MHz, CDCl3): δ = 13.9, 20.3, 31.7, 43.2, 54.2, 66.7,
70.1, 70.4, 82.1, 128.0, 128.5, 136.5, 156.3.
HRMS (ESI): m/z [M + H]+ calcd for C18H29N2O4: 337.2127; found:
337.2111.© Georg Thieme Verlag  Stuttgart · New York — Synthesis 2017, 49, 2088–2100
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Yield: 95 mg (78%); light-brown solid; mp 144–146 °C; [α]D 10.4 (c
0.5, CH2Cl2).
1H NMR (500 MHz, CDCl3): δ = 0.81–0.95 (m, 3 H), 1.21–1.41 (m,
15 H), 1.42–1.50 (m, 2 H), 1.85–1.99 (m, 2 H), 2.52–2.70 (m, 3 H),
2.81–2.95 (m, 1 H), 3.60–3.71 (m, 1 H), 3.91–4.01 (m, 1 H), 4.02–4.11
(m, 2 H), 4.31–4.41 (m, 1 H), 5.14 (br s, 2 H), 5.62–5.70 (m, 1 H), 7.31–
7.49 (m, 5 H).
13C NMR (125.8 MHz, CDCl3): δ = 14.1, 22.6, 27.1, 29.3, 29.4, 29.5,
29.6, 31.8, 43.3, 49.5, 54.2, 66.7, 70.0, 70.2, 82.1, 128.1, 128.4, 136.5,
156.4.




Yield: 140 mg (50%); light-brown solid; mp 157–158 °C; [α]D 18 (c
0.5, CHCl3).
1H NMR (400 MHz, CDCl3): δ = 1.81–2.01 (m, 2 H), 2.49–2.61 (m, 1 H),
2.81–2.91 (m, 1 H), 3.59–3.67 (m, 1 H), 3.68–3.85 (m, 2 H), 3.91–4.15
(m, 4 H), 4.21–4.40 (m, 1 H), 5.12 (br s, 2 H), 5.61–5.75 (m, 1 H), 7.26–
7.49 (m, 10 H).
13C NMR (125.8 MHz, CDCl3): δ = 27.6, 40.9, 51.7, 52.2, 64.7, 68.1,
68.4, 80.1, 125.6, 126.1, 126.2, 126.3, 126.5, 126.6, 126.7, 126.8, 134.5,
136.3, 154.2.
HRMS (ESI): m/z [M + H]+ calcd for C21H27N2O4: 371.1971; found:
371.1942.
C2-Alkylamino Jaspine B Analogues 20a–c; General Procedure
The N-Cbz protected alkyl amine analogues 20a–c were heated at re-
flux in aqueous 6 M HCl solution (excess) for 12–16 h. Upon comple-
tion of reaction (monitored by TLC), the reaction mixture was ex-
tracted once with dichloromethane to remove any organic impurities
and the aqueous layer was concentrated under vacuum. Drying of the
resulting products under high vacuum overnight afforded the corre-




Yield: 32 mg (80%); light-brown hygroscopic solid; [α]D 13.6 (c 0.44,
CH3OH).
1H NMR (500 MHz, CD3OD): δ = 0.95–1.05 (m, 3 H), 1.35–1.51 (m,
2 H), 1.65–1.81 (m, 2 H), 1.95–2.05 (m, 1 H), 2.11–2.21 (m, 1 H), 2.93–
3.01 (m, 2 H), 3.15–3.24 (m, 2 H), 3.83–4.01 (m, 4 H), 4.35–4.46 (m,
1 H).
13C NMR (125.8 MHz, CD3OD): δ = 14.0, 20.9, 25.5, 26.1, 26.9, 29.3,
30.3, 47.0, 54.2, 69.5, 71.1, 81.8.




Yield: 43 mg (78%); light-brown hygroscopic solid; [α]D 2.8 (c 1.12,
CH3OH).
1H NMR (500 MHz, CD3OD): δ = 0.89 (br s, 3 H), 1.30 (br s, 14 H), 1.69
(br s, 2 H), 1.95–2.05 (m, 1 H), 2.07–2.18 (m, 1 H), 3.0 (br s, 2 H), 3.18
(br s, 2 H), 3.88–3.97 (m, 4 H), 4.36 (br s, 1 H).
13C NMR (125.8 MHz, CD3OD): δ = 11.8, 21.1, 24.2, 24.6, 25.0, 27.6,
27.8, 27.9, 28.0, 30.4, 44.2, 51.5, 66.8, 68.4, 79.1.




Yield: 40 mg (57%); light-brown hygroscopic solid; [α]D –22.7 (c 0.43,
CH3OH).
1H NMR (400 MHz, CD3OD): δ = 1.91–2.05 (m, 1 H), 2.09–2.21 (m,
1 H), 3.11–3.21 (m, 2 H), 3.75–4.01 (m, 4 H), 4.12–4.28 (m, 2 H), 4.34
(br s, 1 H), 7.42–7.61 (m, 5 H).
13C NMR (125.8 MHz, CD3OD): δ = 26.7, 46.6, 52.4, 54.2, 69.5, 71.1,
81.8, 130.3, 130.5, 130.7, 131.1, 132.5.
HRMS (ESI): m/z [M + H]+ calcd for C13H21N2O2: 237.1603; found:
237.1604.
C4-N,N′-Di-Boc-guanidine Jaspine B (21)
To a stirred solution of jaspine B (25 mg, 83.19 mmol) in 1,4-dioxane
(2 mL) at r.t., was added N,N′-Di-Boc-N′′-triflylguanidine13 (93.5 mg,
249.6 mmol) and triethylamine (24 mg, 249.6 mmol). After stirring
for 6 h, the reaction mixture was concentrated and the residue was
partitioned between chloroform and water. The organic layer was
separated, and the aqueous layer was extracted with CHCl3 (3 × 10
mL). The combined organic extract was dried over anhydrous Na2SO4,
solvent removed under vacuum, and the residue was purified by flash
chromatography (EtOAc/hexanes, 12:88) to afford the product 21.
Yield: 24 mg (58%); white solid; mp 111–114 °C; [α]D 6.3 (c 0.19,
CH2Cl2).
1H NMR (500 MHz, CDCl3): δ = 0.71–0.93 (m, 3 H), 1.21–1.39 (m,
25 H), 1.48–1.54 (m, 15 H), 1.56–1.59 (m, 2 H), 1.61–1.71 (m, 2 H),
1.95 (br s, 1 H), 3.58–3.71 (m, 1 H), 3.75–3.88 (m, 1 H), 4.11–4.28 (m,
2 H), 4.71–4.89 (m, 1 H), 8.91 (br s, 1 H), 11.48 (br s, 1 H).
13C NMR (125.8 MHz, CDCl3): δ = 14.1, 22.7, 28.0, 28.3, 28.9, 29.3,
29.4, 29.5, 29.6, 29.7, 29.8, 31.9, 54.0, 70.2, 72.1, 79.5, 82.1, 83.3,
153.0, 156.2, 163.5.
HRMS (ESI): m/z [M + H]+ calcd for C29H56N3O6: 542.4169; found:
542.4123.
4-Guanidino Jaspine B (22)
The N,N′-di-Boc-analogue 21 (36 mg, 0.067 mmol) was dissolved in a
solution of CH2Cl2 and TFA (1:1, 2 mL) and stirred at r.t. for 4 h. The
reaction mixture was concentrated under vacuum and the residual
liquid was flushed with dichloromethane (2 × 3 mL). The resulting
residue was triturated with hot dichloromethane/hexane (2:1, 15
mL). Drying of the product under high vacuum afforded the trifluoro-
acetate salt of C4-guanidino jaspine B (22).
Yield: 20 mg (90%); white solid; [α]D 2.2 (c 0.01, CH3OH).
1H NMR (500 MHz, CD3OD): δ = 0.87–0.95 (m, 3 H), 1.18–1.51 (m,
24 H), 1.58–1.71 (m, 2 H), 3.55–3.71 (m, 1 H), 3.75–3.84 (m, 1 H),
3.99–4.08 (m, 1 H), 4.15–4.25 (m, 2 H).
13C NMR (125.8 MHz, CDCl3): δ = 13.0, 22.2, 22.3, 25.7, 28.7, 29.0,
29.2, 29.3, 29.4, 31.3, 31.6, 54.3, 68.7, 70.3, 78.0, 82.6, 157.2.
HRMS (ESI): m/z [M + H]+ calcd for C19H40N3O2: 342.3121; found:
342.3106.© Georg Thieme Verlag  Stuttgart · New York — Synthesis 2017, 49, 2088–2100
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l.4-Azido Jaspine B (23)
Step 1: To an ice-cooled solution of NaN3 (157 mg, 2.42 mmol) in wa-
ter (1 mL) was added dichloromethane (1 mL), followed by freshly
distilled trifluoromethanesulfonic anhydride (339 mg, 1.2 mmol) un-
der vigorous stirring. After stirring for 2 h at 0 °C, the organic phase
was separated and the aqueous layer was extracted with dichloro-
methane (3 × 2 mL). The combined organic extract was washed se-
quentially with saturated aqueous NaHCO3 solution, water, brine, and
dried over anhydrous Na2SO4.
Step 2: To a solution of jaspine B hydrochloride salt (45 mg, 0.134
mmol) in dichloromethane (1 mL) at r.t. was added triethylamine
(40.5 mg, 0.401 mmol). After cooling to 0 °C (ice-bath), the solution
was treated with slow dropwise addition of the triflyl azide from Step
1 above. The reaction mixture was allowed to attain r.t. and stirred for
2 h. The reaction was quenched with saturated aqueous NaHCO3 solu-
tion (3 mL) and the organic layer was separated. The aqueous layer
was extracted with dichloromethane (3 × 3 mL) and the combined ex-
tract was washed with brine, dried over anhydrous Na2SO4, and fil-
tered. Removal of solvent under vacuum and purification of the resi-
due by flash chromatography (EtOAc/hexanes, 1:9) afforded C4-
azido-jaspine B analogue 23.
Yield: 34 mg (71%); white solid; [α]D 11.8 (c 0.5, CHCl3).
IR (neat): 3330, 2916, 2848, 2102 cm–1.
1H NMR (400 MHz, CDCl3): δ = 0.85–0.92 (m, 3 H), 1.16–1.46 (m,
24 H), 1.57–1.71 (m, 2 H), 1.95–2.17 (m, 1 H), 3.73–3.92 (m, 2 H),
3.95–4.04 (m, 1 H), 4.09–4.26 (m, 2 H).
13C NMR (125.8 MHz, CDCl3): δ = 14.1, 22.6, 22.7, 26.1, 28.9, 29.4,
29.5, 29.6, 29.7, 31.6, 31.9, 63.7, 68.4, 72.5, 82.1, 125.0, 133.9.
(2S,3S,4S)-4-(4-Propyl-1H-1,2,3-triazol-1-yl)-2-tetradecyltetrahy-
drofuran-3-ol (24)
To a solution of C-4-azido jaspine B (23; 40 mg, 0.123 mmol) in t-
BuOH and H2O (1:1, 2 mL) was added 1-pentyne (18.4 mg, 0.27
mmol), CuSO4 (15.4 mg, 0.0984 mmol), and L-sodium ascorbate (10
mg, 0.0490 mmol). The resulting mixture was stirred at r.t. for 20 h.
Upon completion of reaction (tlc monitoring), the reaction mixture
was concentrated under vacuum, and the residue was purified by
flash chromatography (EtOAc/hexanes, 15:85) to afford 4-(1,4-disub-
stituted triazolo)jaspine B (24).
Yield: 26 mg (67%); white powder; mp 170–171 °C; [α]D 14.8 (c 0.28,
CH2Cl2).
1H NMR (400 MHz, CDCl3): δ = 0.93–0.97 (m, 6 H), 1.19–1.41 (m,
22 H), 1.62–1.81 (m, 5 H), 2.54–2.69 (m, 2 H), 3.61 (br s, 1 H), 3.89–
4.03 (m, 1 H), 4.11–4.31 (m, 2 H), 4.41–4.60 (m, 1 H), 5.18–5.31 (m,
1 H), 7.43 (s, 1 H).
13C NMR (125.8 MHz, CDCl3): δ = 13.7, 14.1, 22.4, 22.7, 26.1, 27.6,
28.9, 29.3, 29.5, 29.6, 29.7, 31.9, 63.5, 68.5, 71.8, 83.0, 121.1, 147.7.




To a stirred solution of C-4-azido jaspine B (23; 15 mg, 0.046 mmol)
in anhydrous THF (2 mL) was added chloro(pentamethylcyclopenta-
dienyl)bis(triphenylphosphine)ruthenium(II) (3 mg, 0.004 mmol)
and 1-pentyne (33 mg, 0.46 mmol). After heating the mixture to re-
flux for 24 h, solvent was removed under vacuum, and the residue
was purified by flash chromatography (EtOAc/hexanes, 1: 4) to afford
4-(1,4-disubstituted triazolo) jaspine B 25.
Yield: 11 mg (61%); light-brown solid; mp 160–163 °C; [α]D 14.3 (c
0.4, CH2Cl2).
1H NMR (400 MHz, CDCl3): δ = 0.81–1.0 (m, 6 H), 1.03–1.17 (m, 4 H),
1.18–1.61 (m, 20 H), 1.51–1.91 (m, 4 H), 2.68–2.79 (m, 2 H), 3.58–
3.80 (m, 1 H), 3.81–3.99 (m, 1 H), 4.01–4.32 (m, 1 H), 4.38–4.51 (m,
2 H), 4.79–4.99 (m, 1 H), 7.41 (br s, 1 H).
13C NMR (125.8 MHz, CDCl3): δ = 13.8, 14.1, 21.5, 22.7, 25.2, 26.0,
28.8, 29.4, 29.6, 29.7, 31.9, 60.4, 68.6, 72.2, 83.5, 121.4, 147.7.
HRMS (ESI): m/z [M + H]+ calcd for C23H44N3O2: 394.3434; found:
394.3440.
Cytotoxicity Assays
In cytotoxicity evaluation studies, the jaspine B analogues were eval-
uated in murine B16 melanoma cells by using a homogeneous re-
sazurin (Alamar Blue) assay.18 Stock solutions (1 mM) of compounds
were serially diluted in cell-culture medium (RPMI-1640 supple-
mented with 10 mM L-glutamine, and 10% fetal bovine serum) across
a 384-well plate, resulting in 40 μL in each well. Aliquots (40 μL) of
cells suspended in cell-culture medium at a density of 106 cells/well
were added to the plate and incubated for 48 h in a humidified atmo-
sphere (37 °C, 5% CO2). At the end of the incubation period, 40 μL of
the supernatant was removed and an equal volume of 2X resazurin
(200 mg/mL) was added and incubated for an additional 4 h. Conver-
sion of resazurin into resorufin was quantified by ratiometric absorp-
timetry at 570/610 nm and plotted as a function of the concentration
of compounds, from which average IC50 values were derived by con-
ventional four-parameter logistic curve-fitting using GraphPad Prism.
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